Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder.
Virginia Saurman, Kara G Margolis, Ruth Ann Luna
https://pubmed.ncbi.nlm.nih.gov/32056091/Actively Recruiting
Phase Not Applicable
Age: 3Years - 6Years
All Genders
ID06514573
Study of Oral Butyrate Supplement to Improve Gut and Behavioral Symptoms in Children Aged 3 to 6 Years with Autism Spectrum Disorder and Gut Disorders
Led by Istituto Superiore di Sanità · Updated on 2025-05-02
128
Participants Needed
3
Research Sites
17 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of a 16-week oral postbiotic supplementation, specifically sodium butyrate, on children aged 3 to 6 years with Autism Spectrum Disorder ASD who also have functional gastrointestinal disorders FGIDs. ASD is a complex neurodevelopmental condition often accompanied by FGIDs, which worsen ASD symptoms and complicate management, especially in non-verbal children. This study aims to assess how treating FGIDs may impact the behavioral and core symptoms of ASD, while also identifying factors that predict response to treatment using artificial intelligence techniques.
CONDITIONS
Brief Title
Butyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders
Research Team
M
Maria Luisa Scattoni, Ph.D.
M
Maria Puopolo, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here